Literature DB >> 25451054

The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans.

Nathan P Wiederhold1, Laura K Najvar2, Annette W Fothergill3, Rosie Bocanegra2, Marcos Olivo2, Dora I McCarthy3, William R Kirkpatrick2, Yoshiko Fukuda4, Junichi Mitsuyama4, Thomas F Patterson2.   

Abstract

We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans. T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25451054      PMCID： PMC4335842          DOI： 10.1128/AAC.04228-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).

Authors:  Michael A Pfaller; Shawn A Messer; Gary J Moet; Ronald N Jones; Mariana Castanheira
Journal:  Int J Antimicrob Agents       Date:  2011-04-22       Impact factor: 5.283

2.  Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans.

Authors:  Nathan P Wiederhold; Jodi L Grabinski; Guillermo Garcia-Effron; David S Perlin; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2008-09-15       Impact factor: 5.191

3.  T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena.

Authors:  Eio Yamada; Hiroshi Nishikawa; Nobuhiko Nomura; Junichi Mitsuyama
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

4.  Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie A Bocanegra; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

5.  In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.

Authors:  Junichi Mitsuyama; Nobuhiko Nomura; Kyoko Hashimoto; Eio Yamada; Hiroshi Nishikawa; Makoto Kaeriyama; Akiko Kimura; Yozo Todo; Hirokazu Narita
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

6.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

7.  Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice.

Authors:  L K Najvar; R Bocanegra; N P Wiederhold; C Lambros; N Najarian; T F Patterson; J R Graybill
Journal:  Clin Microbiol Infect       Date:  2008-04-05       Impact factor: 8.067

8.  T-2307 causes collapse of mitochondrial membrane potential in yeast.

Authors:  Tatsuya Shibata; Toshinari Takahashi; Eio Yamada; Akiko Kimura; Hiroshi Nishikawa; Hiroyoshi Hayakawa; Nobuhiko Nomura; Junichi Mitsuyama
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

Review 9.  Epidemiology of candidaemia and invasive candidiasis. A changing face.

Authors:  Guillermo Quindós
Journal:  Rev Iberoam Micol       Date:  2013-11-19       Impact factor: 1.044

Review 10.  Epidemiology and risk factors for invasive candidiasis.

Authors:  Nur Yapar
Journal:  Ther Clin Risk Manag       Date:  2014-02-13       Impact factor: 2.423
View more
  10 in total

1.  The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie Jaramillo; Marcos Olivo; Hoja Patterson; April Connell; Yoshiko Fukuda; Junichi Mitsuyama; Gabriel Catano; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata.

Authors:  Nathan P Wiederhold; Laura K Najvar; Annette W Fothergill; Rosie Bocanegra; Marcos Olivo; Dora I McCarthy; Yoshiko Fukuda; Junichi Mitsuyama; Thomas F Patterson
Journal:  J Antimicrob Chemother       Date:  2015-11-29       Impact factor: 5.790

Review 3.  Novel Antifungal Agents and Their Activity against Aspergillus Species.

Authors:  Roya Vahedi-Shahandashti; Cornelia Lass-Flörl
Journal:  J Fungi (Basel)       Date:  2020-10-09

Review 4.  Antifungal resistance: current trends and future strategies to combat.

Authors:  Nathan P Wiederhold
Journal:  Infect Drug Resist       Date:  2017-08-29       Impact factor: 4.003

5.  The Novel Arylamidine T-2307 Selectively Disrupts Yeast Mitochondrial Function by Inhibiting Respiratory Chain Complexes.

Authors:  Kohei Yamashita; Taiga Miyazaki; Yoshiko Fukuda; Junichi Mitsuyama; Tomomi Saijo; Shintaro Shimamura; Kazuko Yamamoto; Yoshifumi Imamura; Koichi Izumikawa; Katsunori Yanagihara; Shigeru Kohno; Hiroshi Mukae
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 6.  Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.

Authors:  Sarah E Murphy; Tihana Bicanic
Journal:  Front Cell Infect Microbiol       Date:  2021-12-14       Impact factor: 6.073

Review 7.  Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.

Authors:  Nathan P Wiederhold
Journal:  J Fungi (Basel)       Date:  2022-08-16

Review 8.  New Horizons in Antifungal Therapy.

Authors:  Kaila M Pianalto; J Andrew Alspaugh
Journal:  J Fungi (Basel)       Date:  2016-10-02

Review 9.  Hope on the Horizon: Novel Fungal Treatments in Development.

Authors:  Adriana M Rauseo; Ariella Coler-Reilly; Lindsey Larson; Andrej Spec
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835

Review 10.  Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris.

Authors:  Muriel Billamboz; Zeeshan Fatima; Saif Hameed; Samir Jawhara
Journal:  Microorganisms       Date:  2021-03-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.